Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.

Conferences ramp up, and ASH abstracts near.

Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?

MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.

But the FDA’s investigation looks like worse news for autoimmune disease than oncology.

Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.